Cargando…
Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective
Autologous chimeric antigen receptor-T (CAR-T) cell therapy has proven itself as an effective therapeutic modality for cancers, especially hematological malignancies and is emerging as a potential candidate for solid organ cancers as well. However, the accessibility to treatment has been limited due...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751310/ https://www.ncbi.nlm.nih.gov/pubmed/36531042 http://dx.doi.org/10.3389/fonc.2022.1062296 |
_version_ | 1784850441103736832 |
---|---|
author | Ramakrishnan, Sharanya Kumar, Jeevan Datta, Suvro Sankha Radhakrishnan, Vivek Nair, Reena Chandy, Mammen |
author_facet | Ramakrishnan, Sharanya Kumar, Jeevan Datta, Suvro Sankha Radhakrishnan, Vivek Nair, Reena Chandy, Mammen |
author_sort | Ramakrishnan, Sharanya |
collection | PubMed |
description | Autologous chimeric antigen receptor-T (CAR-T) cell therapy has proven itself as an effective therapeutic modality for cancers, especially hematological malignancies and is emerging as a potential candidate for solid organ cancers as well. However, the accessibility to treatment has been limited due to complexities and costs associated with manufacturing a genetically modified autologous product. The centralized model of CAR-T manufacturing which has emerged as the dominant model in developed nations does not seem well-suited to the needs and realities of the developing economies. In this context, we explore the relative advantages and disadvantages of the two models from a developing nation’s perspective. |
format | Online Article Text |
id | pubmed-9751310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97513102022-12-16 Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective Ramakrishnan, Sharanya Kumar, Jeevan Datta, Suvro Sankha Radhakrishnan, Vivek Nair, Reena Chandy, Mammen Front Oncol Oncology Autologous chimeric antigen receptor-T (CAR-T) cell therapy has proven itself as an effective therapeutic modality for cancers, especially hematological malignancies and is emerging as a potential candidate for solid organ cancers as well. However, the accessibility to treatment has been limited due to complexities and costs associated with manufacturing a genetically modified autologous product. The centralized model of CAR-T manufacturing which has emerged as the dominant model in developed nations does not seem well-suited to the needs and realities of the developing economies. In this context, we explore the relative advantages and disadvantages of the two models from a developing nation’s perspective. Frontiers Media S.A. 2022-12-01 /pmc/articles/PMC9751310/ /pubmed/36531042 http://dx.doi.org/10.3389/fonc.2022.1062296 Text en Copyright © 2022 Ramakrishnan, Kumar, Datta, Radhakrishnan, Nair and Chandy https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ramakrishnan, Sharanya Kumar, Jeevan Datta, Suvro Sankha Radhakrishnan, Vivek Nair, Reena Chandy, Mammen Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective |
title | Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective |
title_full | Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective |
title_fullStr | Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective |
title_full_unstemmed | Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective |
title_short | Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective |
title_sort | should we adopt an automated de-centralized model of chimeric antigen receptor- t cells manufacturing for low-and middle-income countries? a real world perspective |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751310/ https://www.ncbi.nlm.nih.gov/pubmed/36531042 http://dx.doi.org/10.3389/fonc.2022.1062296 |
work_keys_str_mv | AT ramakrishnansharanya shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective AT kumarjeevan shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective AT dattasuvrosankha shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective AT radhakrishnanvivek shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective AT nairreena shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective AT chandymammen shouldweadoptanautomateddecentralizedmodelofchimericantigenreceptortcellsmanufacturingforlowandmiddleincomecountriesarealworldperspective |